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Neuronatin (Nnat) is an imprinted gene implicated in human obesity and widely expressed
in neuroendocrine and metabolic tissues in a hormone- and nutrient-sensitive manner.
However, its molecular and cellular functions and precise role in organismal physiology
remain only partly defined. Here we demonstrate that mice lacking Nnat globally or
specifically in b cells display impaired glucose-stimulated insulin secretion leading to
defective glucose handling under conditions of nutrient excess. In contrast, we report no
evidence for any feeding or body weight phenotypes in global Nnat-null mice. At the
molecular level neuronatin augments insulin signal peptide cleavage by binding to the
signal peptidase complex and facilitates translocation of the nascent preprohormone. Loss
of neuronatin expression in b cells therefore reduces insulin content and blunts glucose-
stimulated insulin secretion. Nnat expression, in turn, is glucose-regulated. This mechanism
therefore represents a novel site of nutrient-sensitive control of b cell function and whole-
animal glucose homeostasis. These data also suggest a potential wider role for Nnat in the
regulation of metabolism through the modulation of peptide processing events.
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Introduction
Imprinted genes display monoallelic expression according to par-
ent of origin due to epigenetic events initiated in the germline 
(1). Around 150 such genes have been identified in mice, 50% 
of which have also been found in humans. Although its origins 
remain obscure, mouse and human genetic studies have revealed 
key roles for genomic imprinting in regulating both development 
and various aspects of postnatal physiology. For example, many 
imprinted genes regulate placental function, fetal and neonatal 
growth, and early-life metabolism and behavior (2). Furthermore, 
a number of human syndromes with fetal and postnatal growth 
and metabolic phenotypes, such as Prader-Willi, Angelman, and 
Beckwith-Wiedemann syndromes, result from abnormalities 
in the expression of specific imprinted genes (2). Despite these 
advances, for the majority of imprinted genes, the precise cellular 
and molecular mechanisms through which their effects on growth 
and metabolism are mediated remain unclear.
Neuronatin (Nnat) is a paternally expressed imprinted pro-
teolipid-encoding gene originally identified in the developing rat 
brain but also found in all placental mammals, including humans. 
It is expressed predominantly in the neuroendocrine systems of 
the developing fetus and adult but is also found in adipose tissue 
(3–5). The Nnat locus resides in a “microimprinted” region with-
in the intronic sequence of the neighboring gene Blcap, with dif-
ferential expression controlled by localized methylation of the 
silenced maternal allele (6–10). In vivo studies have shown that 
Nnat expression is dynamically regulated by nutrient status. For 
example, fasting and leptin administration down- and upregulate 
Nnat mRNA levels in the hypothalamus, respectively (11–13). Nutri-
ent-dependent changes in expression are also seen in white adi-
pose tissue and pancreatic β cells, and altered expression is found 
in the adipose tissue and islets of rodent models of obesity and dia-
betes (5, 14–16). Furthermore, recent evidence suggests that Nnat 
expression in mice, together with a cluster of other imprinted genes 
under the regulation of the chromatin-interacting protein TRIM28, 
underpins the “stochastic” development of obesity seen in inbred 
mouse strains (17). Single-nucleotide polymorphisms in the human 
NNAT locus are associated with extreme childhood obesity, and 
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atic islet cells, and reverse transcription PCR (RT-PCR) and West-
ern blotting analysis confirmed the absence of neuronatin expres-
sion in tissues of homozygous neuronatin-knockout (Nnat–/–) mice 
(Figure 1, B and C). Heterozygous mice receiving the mutant allele 
from the paternal side (Nnat+/–p) had undetectable levels of expres-
sion in islets, hypothalamus, and white adipose tissue (WAT) at 
the mRNA and protein level, indicating that the imprinting status 
of Nnat was maintained in the mutant animals. In contrast, het-
erozygous mice receiving the mutant allele from the maternal side 
(Nnat+/–m) displayed wild-type levels of Nnat expression (Figure 1, 
B and C). Targeting of Nnat did not affect expression of the bial-
lelic gene Blcap found at the same locus (Supplemental Figure 1A; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI120115DS1).
In view of the existing evidence for a role for Nnat in energy 
homeostasis regulation, we assessed body weight and also feeding 
behavior (ad libitum, after fasting and in response to exogenous 
leptin). However, these were all unaltered in male Nnat+/–p mice 
compared with their WT littermates (Supplemental Figure 1, B–E). 
In contrast, when we analyzed glucose homeostasis we found that 
male Nnat+/–p mice displayed a defect in GSIS in vivo compared with 
WT littermates, with the complete absence of an increase from 
basal insulin levels, as well as unexpected basal hyperinsulinemia 
(Supplemental Figure 1F). This GSIS abnormality, which resulted 
in the loss of both phases of classical biphasic insulin secretion, 
was present in male knockout mice on both C57BL/6J and 129S2/
Sv backgrounds (Supplemental Figure 1, F and G and insets).
To determine whether the perturbed GSIS seen in global 
Nnat+/–p mice was due to a β cell–intrinsic defect, and because islet 
neuronatin expression is almost exclusively restricted to β cells 
(Supplemental Figure 1H), we generated a β cell–specific knock-
out line by crossing our Nnatfl (floxed) line with mice harboring 
Cre recombinase knocked in at the Ins1 locus. This deleter strain 
catalyzes efficient (~95%) recombination highly selectively in the 
β cell, with undetectable activity at extrapancreatic sites (22, 23). 
RT-PCR and Western blotting confirmed loss of Nnat expression 
specifically in pancreatic islets of heterozygous mice with a floxed 
Nnat allele from the paternal side (βcellKO-Nnat+/–p) but not from 
the maternal side (βcellKO-Nnat+/–m) and with no alterations in 
Blcap expression (Supplemental Figure 1, I–K). While WT, Cre-pos-
itive, floxed, and βcellKO-Nnat+/–m mice all had normal GSIS (and 
were combined as controls), this was essentially abolished in male 
βcellKO-Nnat+/–p mice (Figure 1D), indicating that the GSIS pheno-
type is β cell–autonomous. When exposed to a Western diet for 12 
weeks, control mice retained biphasic GSIS (Supplemental Figure 
1L). In contrast, βcellKO-Nnat+/–p mice did not display a normal 
hyperinsulinemic response to overnutrition, with persistence of 
the defect in GSIS previously seen on chow diet (control: 3.5-fold 
increase in basal insulin levels with Western diet vs. 2.2-fold in 
βcellKO-Nnat+/–p mice, n = 7 per genotype, P = 0.0021; Supplemen-
tal Figure 1L and inset). Fasting blood glucose, which was unaffect-
ed in chow-fed mice, progressively increased in βcellKO-Nnat+/–p 
animals compared with controls during exposure to Western diet 
(Figure 1E). Glucose tolerance was unaffected by Nnat deletion in 
chow-fed mice (Supplemental Figure 1M). However, a progressive 
deterioration in glucose tolerance was seen over a 12-week period 
in male βcellKO-Nnat+/–p mice on the Western diet (Figure 1, F and 
reduced NNAT expression has been reported in the adipose tissue 
of obese children (13, 17). Together, these findings suggest a role 
for neuronatin in the regulation of body weight and the pathophys-
iology of obesity, although the molecular mechanisms underlying 
these observations remain undetermined.
While to date no direct in vivo evidence has been provided for 
a role for Nnat in the regulation of glucose homeostasis, in vitro 
studies manipulating its expression in cultured pancreatic β cells 
suggest that Nnat may regulate glucose-stimulated insulin secre-
tion (GSIS) (14, 18). In terms of the potential mechanisms under-
lying this observation, in vitro studies have shown that NNAT is 
present in the endoplasmic reticulum (ER) (14, 19) and, in part 
owing to a suggested structural resemblance to the calcium-han-
dling protein phospholamban, have implicated this protein in the 
control of intracellular calcium dynamics (3, 5, 14, 20). Involve-
ment in the control of ion channels, Ca2+ ATPases, and glucoki-
nase has also been proposed (21).
Despite the above evidence implicating Nnat in the control 
of GSIS, a defined molecular and cellular mechanism that might 
underpin this role has yet to be defined. Furthermore, as no 
detailed characterization of an Nnat-deficient mouse model has 
previously been described, the precise in vivo functions of Nnat, 
with respect to pancreatic islet function and specifically to the dis-
tinct events regulating GSIS, remain unclear.
Here, we reveal that in vivo deletion of Nnat either globally or 
specifically in β cells causes defective GSIS, leading to impaired 
glucose tolerance under conditions of nutrient overload. Thus, 
Nnat is required for normal pancreatic β cell insulin secretion. In 
contrast, we find little evidence for any feeding or body weight 
phenotypes in global Nnat-null mice. We further demonstrate that 
NNAT binds to the signal peptidase complex (SPC) and facilitates 
the translocation of nascent preproinsulin into the ER. Impair-
ment of preproinsulin signal peptide (SP) cleavage in β cells leads 
to a deficiency of available mature insulin secretory granules and 
defective GSIS. Neuronatin expression itself is regulated by glu-
cose, and so, together, these studies identify a novel component of 
the insulin processing apparatus, illustrate the important contri-
bution of the SPC to the molecular events involved in the control 
of GSIS, and thus define a previously unrecognized site of nutri-
ent-sensitive control of β cell function and whole-animal glucose 
homeostasis. Our studies also suggest a potentially wider role for 
Nnat in the regulation of a range of peptide secretory processes 
relevant to growth and metabolism.
Results
Mice with targeted deletion of the Nnat gene display defective GSIS. To 
explore the role of Nnat in whole-body metabolism, we generated 
mice with global deletion of the Nnat gene (Figure 1A). A floxed 
Nnat allele (Nnatfl) was first created in embryonic stem cells by 
the introduction of loxP sites flanking exon 1. A globally Nnat-null 
mouse line (Nnat+/–) was then established following permanent 
excision of the flanked region by crossing of Nnat+/fl mice with 
germline Cre recombinase–expressing deleter mice. Globally null 
Nnat–/– animals backcrossed onto the C57BL/6J strain background 
were viable and fertile and were born with a normal Mendelian 
ratio with normal litter sizes. In adult mice, neuronatin is primarily 
expressed in adipose tissue, hypothalamus, pituitary, and pancre-
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animals. Impairment of GSIS on a chow diet was not due to a 
reduction in β cell mass or disruption of islet architecture (Supple-
mental Figure 2, A and B). Furthermore, there was no reduction in 
β cell mass in βcellKO-Nnat+/–p mice following Western diet feed-
ing (control: 1.74 ± 0.36 mg vs. 1.49 ± 0.30 mg in βcellKO-Nnat+/–p 
mice, n = 5 per genotype, P = 0.5476), suggesting that the deficit 
in GSIS on this diet was not due to loss of β cells. The expression 
of key markers of the mature β cell, including Glut2 (Slc2a2), Neu-
rod1, Ins2, Pdx1, and Nkx6.1, was unaltered in islets from global 
Nnat-knockout animals, as were serum glucagon levels (Supple-
mental Figure 2, C and D).
Manipulating expression of NNAT in β cells and other cell 
types has previously been demonstrated to perturb intracellular 
Ca2+ homeostasis and dynamics, and it has been suggested that 
this underlies the defect in GSIS found after in vitro knockdown of 
Nnat (5, 14, 20). In contrast, we obtained no evidence for altered 
G). No differences in body weight or insulin sensitivity were appar-
ent between groups (Supplemental Figure 1, N and O), suggesting 
a progressive decline in β cell function rather than insulin action 
in mutant mice with overnutrition. This view was further support-
ed by in vitro studies using islets isolated from both global Nnat+/–p 
and conditional βcellKO-Nnat+/–p mice on a C57BL/6J background, 
which revealed a marked impairment in GSIS in the mutant β cells 
(global KO: 4.8-fold insulin secretion increase with high glucose in 
WT vs. 2.0-fold in Nnat+/–p, n = 12, P = 0.0401; β cell conditional 
KO: 7.2-fold increase in controls vs. 4.2-fold in βcellKO-Nnat+/–p, n = 
8, P = 0.0207; Figure 2, A and B, respectively). Taken together these 
findings indicate that in vivo, Nnat regulates β cell function but has 
no effect on body weight and feeding behavior.
Nnat-deficient primary β cells have a defect in insulin storage. 
Next, we explored a number of cellular and molecular mecha-
nisms potentially responsible for defective GSIS in Nnat-mutant 
Figure 1. Effect of Nnat deficiency in vivo. (A) Targeted inactivation of the Nnat gene. Exon 1 was flanked by loxP sites with the neomycin selection cassette 
(Neo) flanked by FRT sites, to produce a floxed and null allele. (B and C) Quantitative RT-PCR and representative Western blot analysis of Nnat expres-
sion in tissues of WT, heterozygous Nnat+/–m (maternal deletion), heterozygous Nnat+/–p (paternal deletion), and homozygous Nnat–/– mice on C57BL/6J 
background. Data are compared with WT mice (n = 4–7 animals per group, Kruskal-Wallis or Mann-Whitney U test). (D) Measurement of insulin secretion in 
vivo in response to i.p. glucose in 10-week-old male βcellKO-Nnat+/–p versus control mice on C57BL/6J background (n = 8 animals per genotype, ANOVA with 
repeated measures). Inset shows box-and-whisker plot of the same data plotted as percentage insulin secretion across all time points compared with basal 
insulin values (at T = 0). (“‡” indicates statistically significant increases, P < 0.05, in secretion in WT mice compared with basal insulin values.) (E) Fasted 
(4-hour) blood glucose levels from 10-week-old chow-fed male βcellKO-Nnat+/–p versus control mice and from male mice of both genotypes fed Western diet 
for 4 weeks (14 weeks old) and 12 weeks (22 weeks old) (Student’s t test for each time point, all C57BL/6J, n = 7–14 animals per genotype, per time point, 
minimum 2 independent cohorts). (F and G) Glucose tolerance in overnight-fasted Western diet–fed groups as in E (ANOVA with repeated measures). Insets 
show means of area under the curve (AUC) for both genotypes at both time points (Student’s t test for each). (*P < 0.05, **P < 0.01.).
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microscopy, with Nnat+/–p β cells showing 
a reduction of mature insulin–containing 
dense core secretory granules, and an 
increased proportion of partially filled, 
or even “empty” (electron-translucent), 
granules (Figure 3, A–C). Together, these 
observations suggest a key in vivo role for 
Nnat in maintaining sufficient insulin con-
tent in pancreatic β cells for normal GSIS.
Neuronatin interacts with the SPC. To 
gain further insights into the molecular 
roles of neuronatin, and provide potential 
mechanisms for our in vivo observations 
above, we used an unbiased affinity puri-
fication/mass spectrometry screen with 
the aim of identifying novel interaction 
partners of NNAT. We chose to focus on 
clonal pancreatic β cells in our proteomic 
approach to avoid issues of cellular het-
erogeneity from whole pancreatic islets. 
Protein lysates from MIN6 cells, a mouse 
insulinoma-derived β cell line (24), were 
incubated with antibodies against endog-
enous NNAT, and the immunoprecipitate 
analyzed by mass spectrometry (Figure 
4A and Supplemental Figure 3A). Pro-
teins coimmunoprecipitating with NNAT 
were ranked according to their abundance 
compared with control immunoprecipi-
tates. Strikingly, of the top-ranking pro-
teins in this analysis, 3 were components 
of the signal peptidase complex (SPC), 
namely the catalytic subunit SEC11A and 
signal peptidase complex subunits 1 and 
2 (SPCS1 and SPCS2; Figure 4B and Sup-
plemental Table 1 for full list), a complex 
responsible for cleavage of the signal peptide (SP) from nascent 
preprohormones. To verify the interaction between NNAT and 
the SPC, tagged versions of SEC11A and NNAT were expressed 
in cultured cells. FLAG-tagged NNAT coimmunoprecipitated 
with c-Myc–tagged SEC11A, confirming the association between 
NNAT and the SPC (Figure 4C).
Neuronatin enhances signal peptidase activity in vitro. The role 
of the SPC in the SP cleavage of preproinsulin has, in part, been 
established through the identification of human insulin gene 
mutations that alter preprohormone processing. This, in turn, 
impairs β cell function, leading to a spectrum of diabetic pheno-
types (25, 26). siRNA-mediated transient silencing of Sec11a in the 
INS1E β cell line (27) reduced both insulin content and secretion 
in high-glucose conditions (Figure 4D and Supplemental Figure 3, 
B and C), suggesting a key role of the SPC in insulin maturation 
and subsequent release. Likewise, knockdown of Nnat caused a 
reduction in insulin content and marked blunting of GSIS (Figure 
4D and Supplemental Figure 3, B and C).
To determine whether there is a direct role for NNAT in pre-
proinsulin SP cleavage, we followed this event in newly synthe-
sized preprohormone by pulse-labeling with 35S-methionine/
Ca2+ signaling in islets from Nnat+/–p mice in response to either Ca2+ 
influx provoked by high glucose, or release of Ca2+ from intracel-
lular stores in response to the activation of Gq-coupled muscarinic 
receptors, and the opening of ER-resident inositol (1,4,5)-trisphos-
phate receptors (Supplemental Figure 2E).
To determine whether defective GSIS in Nnat-deficient mice 
was due to a shortage of available cellular insulin, we measured 
mature insulin content in mutant primary islets by ELISA and 
found that it was significantly reduced compared with that in 
WT islets, potentially indicating a defect in insulin storage (Fig-
ure 2C). We also found a similar reduction of proinsulin content 
in islets from mutant mice, and therefore the proinsulin/mature 
insulin ratio was unaltered (Figure 2D and Supplemental Figure 
2F). When primary islets from Nnat+/–p mice were treated with the 
proteasome inhibitor MG132 to prevent degradation of insulin 
precursors, Western blotting of lysates confirmed reduced proin-
sulin and mature insulin content in islets from mutant mice, and 
also the accumulation of unprocessed preproinsulin (Figure 2E). 
In contrast, no reduction in expression was observed for 2 other, 
ER membrane, proteins, ribophorin 1 and IRE1α (Figure 2E). The 
defect in insulin storage was confirmed by transmission electron 
Figure 2. Insulin content and secretion in Nnat-deficient islets. (A) Insulin secretion in static incuba-
tions of primary isolated islets from 10-week-old male Nnat+/–p and WT mice was determined in vitro 
under low-glucose (3 mM) and high-glucose (16.7 mM) conditions (n = 12 animals per group, 2-way 
ANOVA). (B) Insulin secretion in static incubations of primary isolated islets from 10-week-old male 
control and βcellKO-Nnat+/–p mice was determined as in A (n = 8 mice per genotype, both 3 indepen-
dent experiments). (C and D) Mature insulin content (C) (n = 11 for WT and 8 for Nnat+/–p, Student’s 
t test) and proinsulin content (D) (n = 6 animals per group, Mann-Whitney U test) were quantified 
in isolated islets from 10-week-old male WT and Nnat+/–p mice and normalized to total protein. (E) 
Western blotting analysis of protein levels in primary isolated islets from 10-week-old male Nnat+/–p 
and WT mice. A representative blot of 2 independent experiments (n = 4 mice per genotype, Student’s 
t test) is shown. β-Tubulin was used as a loading control. Mean values for band intensities in multiple 
experiments quantified by densitometry are shown below each panel as well as in associated bar 
charts for insulin species, all expressed relative to WT samples (*P < 0.05, **P < 0.01, ***P < 0.001.).
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preproinsulin targeting to the ER was perturbed in the absence of 
NNAT. Clonal INS1E β cells silenced for Nnat by RNAi were radio-
labeled as above and treated with digitonin to specifically permea-
bilize plasma membranes, leaving internal (ER, secretory granule) 
membranes intact. Treatment of cells with digitonin, and subse-
quent centrifugation, led to a shift of GAPDH from the pellet to 
the supernatant, whereas insulin precursors were retained in the 
pellet in both control and Nnat-silenced cells. Thus, association of 
nascent preproinsulin with the ER is not perturbed upon silenc-
ing of NNAT (Supplemental Figure 4B). This observation indi-
cates that, in the absence of NNAT, preproinsulin is still efficiently 
targeted to the ER membrane. However, it does not exclude the 
possibility that preproinsulin is not fully translocated across the 
ER membrane. To test this, we examined endogenous preproin-
sulin distribution by immunofluorescence in digitonin-treated, 
and thus partially permeabilized, cells, using an antibody that 
detects preproinsulin, proinsulin, and mature insulin. Cells were 
pretreated with MG132 to inhibit the action of the proteasome. 
Preproinsulin staining in digitonin-treated cells was only detected 
upon RNAi silencing of NNAT, suggesting that a portion of pre-
proinsulin was untranslocated and had accumulated in the cytosol 
(Figure 5B). In control cells this observation was virtually absent, 
indicating complete translocation into the ER (Figure 5B). Stain-
ing of mature insulin, which was sequestered in secretory gran-
ules, was only present upon permeabilization of all membranes 
using Triton X-100 (Figure 5B). The ER luminal protein protein 
disulfide isomerase (PDI), which was used to monitor permeabili-
zation, was also only stained after Triton X-100 permeabilization, 
in parallel cultures (Figure 5B). Together, these data demonstrate 
that, in the absence of NNAT, preproinsulin is still targeted to the 
ER but exhibits impaired translocation across the ER membrane.
Three of the five SPC subunits reside on the luminal side of 
the ER membrane (SEC11A, SEC11C, SPCS3), including both cat-
alytic subunits, with the bulk of the remaining 2 proteins lying on 
the cytosolic side (SPCS1 and SPCS2) (30, 31). NNAT is a mem-
brane-resident protein (Supplemental Figure 4C), with a proposed 
transmembrane region at the N-terminus. However, the localiza-
tion of the C-terminal region has not been determined. To inter-
rogate the topology of the SPC interaction with NNAT, we used 
in vitro translation to express C-terminally tagged NNAT on mic-
rosomal membranes and assessed susceptibility to proteinase K 
treatment. C-terminally tagged SPCS3 and SEC11A — a region of 
each protein known to be luminal (31) and therefore on the inside 
of the microsome — were used as controls. Translation of NNAT 
in the presence of microsomes did not alter its molecular weight, 
suggesting that NNAT itself is not cleaved or glycosylated (Figure 
cysteine. In cells transfected with a scrambled siRNA control, pre-
proinsulin was rapidly processed to proinsulin and subsequently 
secreted (Figure 4, E and F). In contrast, Nnat silencing reduced 
preproinsulin SP cleavage, with significant preproinsulin accumu-
lation (Figure 4E). Following a 3-hour chase period, we observed 
reduced secretion of proinsulin as well as some intracellular proin-
sulin loss, presumably reflecting degradation (Figure 4F). An even 
more marked defect in SP cleavage and secretion was observed 
upon knockdown of Sec11a (Figure 4, E and F). Together, these 
data suggest that NNAT interacts with, and modulates, preproin-
sulin processing by the SPC.
NNAT resides on the cytosolic face of the ER membrane to regulate 
preproinsulin translocation. To explore the possibility of a direct effect 
of NNAT on signal peptidase activity, we used an in vitro transla-
tion system in which preproinsulin was synthesized in the presence 
of pancreatic microsomes, ER membrane fragments containing 
endogenous signal peptidase (and glycosylation) activity (28, 29). 
Initially, we confirmed that the microsomal membranes were able 
to support proteolytic cleavage of c-Myc–tagged preproinsulin, 
yielding an 11-kDa fragment corresponding to SP-cleaved proin-
sulin (Supplemental Figure 4A). Translation assays involving coex-
pression of c-Myc–tagged preproinsulin and either FLAG-tagged 
NNAT or GFP were then performed, with each reaction including a 
fixed concentration of microsomal membranes as a source of SPC. 
This approach demonstrated that coexpression of NNAT caused a 
small but significant augmentation of the SP processing of newly 
synthesized preproinsulin (Figure 5A) and suggested a key contri-
bution for NNAT in the efficient functioning of the SPC.
Improper processing of preproinsulin might reflect reduced 
enzymatic activity of the SPC and/or failure of efficient prepro-
protein translocation across the ER membrane to the luminal sur-
face where catalytic activity resides. To dissect the potential con-
tribution of NNAT to each process, we first investigated whether 
Figure 3. Insulin secretory granule morphology in Nnat-deficient β cells 
by electron microscopy. (A) Left: Representative electron micrographs of 
β cells from 10-week-old male WT and Nnat+/–p mice in ultrathin sections 
(scale bars: 5 μm). Middle and right: Higher-magnification images showing 
dense core secretory granules (DCSG), nuclei (N), and various mitochondria 
(M) (scale bars: 1 μm). A total of 9 β cells from sections of fixed islets were 
analyzed from 3 different animals per genotype. (B and C) Quantification 
of the number of DCSGs per unit area, and also percentage of partially 
filled DCSGs, using electron microscopy images from WT and Nnat+/–p  
β cells in A (**P < 0.01, both Student’s t test).
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5C). Levels of the glycosylated form of SPCS3, represented by the 
upper band in Figure 5C, was increased in the presence of micro-
somes (31). Although the amount of SPCS3 and SEC11A protein 
was not altered by proteinase K treatment, presumably reflect-
ing sequestration within microsomes, NNAT protein levels were 
substantially reduced in the presence of the protease, indicating 
that its C-terminal region, and indeed the bulk of this protein, is 
located on the cytosolic side of the ER membrane (Figure 5C). We 
further verified this observation in clonal INS1E β cells by fixing 
and permeabilizing cells with digitonin and immunostaining for 
endogenous NNAT with an antibody that recognizes the C-termi-
nal domain. Digitonin treatment was sufficient to allow staining 
of NNAT, but not PDI, which was only stained after permeabiliza-
tion of all membranes using Triton X-100 (Figure 5D). Together, 
these experiments demonstrate that the bulk of the NNAT protein 
and its C-terminus is located on the cytosolic side of the ER mem-
brane, with an N-terminal anchor sequence (Figure 5E).
Nnat expression is glucose-sensitive in rodent β cells. We (11, 15) 
and others (12, 13) have previously shown that Nnat expression 
is responsive to nutritional status in adipose tissue and hypo-
thalamus. In view of the important role of NNAT in insulin SP 
cleavage and GSIS (Figures 1–5), we further examined the reg-
ulation of Nnat expression by glucose. In the present studies, 
acute (6-hour) incubation of isolated mouse islets (Figure 6, A 
and B) or clonal INS1E β cells (Supplemental Figure 5A) with high 
(16.7 mM) glucose caused rapid upregulation of Nnat mRNA and 
protein. Fasting in mice resulted in reduced NNAT protein lev-
els in pancreatic islets, while acute feeding with either high-fat 
diet or Western diet led to increased expression (Figure 6C and 
Supplemental Figure 5B). Changes with similar dynamics were 
observed in adipose tissue (Supplemental Figure 5, C and D) and 
hypothalamus (Supplemental Figure 5E) from the same animals. 
Together, it appears that changes in the cellular levels of NNAT 
in response to nutritional cues, notably glucose, coordinately 
Figure 4. NNAT interaction with the SPC and modulation of preproinsulin handling. (A) Overview of affinity purification/mass spectrometry (AP/MS) 
screen for novel interaction partners of NNAT. Endogenous NNAT was immunoprecipitated (IP) from MIN6 cell lysates and interacting partners in co-IPs 
analyzed by liquid chromatography/mass spectrometry (LC/MS). (B) Heatmap from AP/MS analysis of top protein hits in IPs using antibodies against 
NNAT (NNAT Ab) and control IPs with rabbit immunoglobulins (IgG). Relatively high abundance is shown in yellow and relatively low abundance in blue. 
(C) Lysates from HEK293T cells expressing c-Myc–tagged SEC11A and FLAG-tagged NNAT were immunoprecipitated using anti–c-Myc antibodies. Proteins 
in input and IP samples were detected by Western blotting using anti–c-Myc and anti-FLAG antibodies. Panel shows a representative blot of 3 indepen-
dent experiments. (D) INS1E cells transiently transfected with siRNA targeting Nnat or Sec11a were assayed in vitro for GSIS at low (3 mM) and high (25 
mM) glucose. A scramble siRNA served as a control with data expressed as mean insulin secretion per unit cellular protein. Graph on the right shows 
total insulin content in cell lysates. (n = 9 independent cultures per group, 3 independent experiments, 2-way ANOVA [left graph] and 1-way ANOVA [right 
graph].) (E) INS1E cells transfected with c-Myc–tagged preproinsulin and siRNAs targeting Nnat or Sec11a were pulse-labeled with 35S-Cys/Met. Lysates 
immunoprecipitated with anti–c-Myc agarose were analyzed by autoradiography. Associated bar chart shows preproinsulin and proinsulin band intensities 
in multiple experiments quantified by densitometry and expressed as percentage processing of preproinsulin (n = 3 cultures per group from 3 independent 
experiments, 1-way ANOVA). (F) Similar experiments performed as in E, from 3-hour chase cell lysates (C) and media (M), quantified as in E (n = 4 cultures 
per group from 3 independent experiments, 1-way ANOVA for both C and M). (*P < 0.05, **P < 0.01.)
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regulate subsequent alterations in demand for insulin SP cleav-
age by fluctuating glucose levels.
Discussion
The present studies demonstrate a key and novel role for the 
nutrient-sensitive, imprinted gene neuronatin in the regulation of 
pancreatic β cell function. Through a series of in vitro and in vivo 
approaches, we show that NNAT directly interacts with the SPC to 
regulate the efficiency of preproinsulin signal peptidase cleavage. 
Neuronatin expression itself is glucose-regulated, thus revealing a 
previously unrecognized point of metabolic control for early mat-
uration of insulin and therefore its storage and secretion. Loss of 
Figure 5. ER membrane topology of NNAT and its direct effect on SPC processing. (A) Representative Western blotting analysis of in vitro–translated 
preproinsulin converted to proinsulin in the presence (+) of pancreatic microsomes with and without coexpression of NNAT, expressed as percentage 
processing of preproinsulin. Coexpression of GFP was used as a control (n = 5 reactions per group, *P < 0.05, Mann-Whitney U test). (B) INS1E cells with 
Nnat siRNA knockdown versus scramble siRNA control were permeabilized with digitonin or Triton X-100, immunostained using an antibody that detects 
all insulin species (Insulins, green) and also NNAT (red), and visualized by confocal microscopy. The luminal ER protein PDI (green) was used to assess 
membrane permeabilization, and nuclei were visualized with DAPI. Scale bar: 10 μm. Fields of view were quantified for total fluorescence using ImageJ 
(NIH) from insulin-stained cells permeabilized with digitonin and normalized to cell number (Student’s t test, ***P < 0.001). (C) Representative Western 
blotting analysis of C-terminal c-Myc–tagged SPCS3 and SEC11A, and FLAG-tagged NNAT translated in vitro in the presence (+) or absence (–) of pancreatic 
microsomes and treated with proteinase K (Prot. K) (n = 3 reactions per group, mean vs. absence of microsomes, **P < 0.01, Student’s t test vs. presence 
of microsomes). (D) Immunofluorescent staining of INS1E cells permeabilized with digitonin or Triton X-100 with use of antibodies against NNAT (red) and 
PDI (green) visualized by confocal microscopy. PDI was used to assess membrane permeabilization, and nuclei were visualized with DAPI. Scale bar: 10 μm. 
(E) Topology of NNAT (green) and subunits of the SPC (black) on the ER membrane. The catalytic site for signal peptidase cleavage in SEC11A/C is shown in 
blue (N and C, amino- and carboxy terminal, respectively).
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SP region of preproinsulin (26). These 
mutations disrupt SP cleavage, leading 
to reduced insulin secretion in a domi-
nant fashion, resulting in ER stress and 
β cell apoptosis, in a form of diabetes 
termed mutant insulin gene–induced 
diabetes of youth (MIDY) (25, 26, 40, 
41). The magnitude of this β cell stress 
from mutant insulin species dictates the 
outcome of severe/early-onset or mild/
late-onset diabetes. For example, an 
R6C mutation causes an approximate-
ly 50% reduction in translocation into 
the ER, with untranslocated molecules 
degraded in the cytosol. Successfully 
translocated preproinsulin is efficiently 
processed and secreted, with no evi-
dence for ER stress, resulting in a milder 
form of mid- to late-onset diabetes (40, 
42, 43). In contrast, an A24D insulin 
mutation does not affect preproinsulin 
translocation but completely blocks SP 
cleavage by SPC in the ER lumen, lead-
ing to misfolding and accumulation of unprocessed preproinsulin 
and subsequent ER stress, β cell failure, and neonatal diabetes (41, 
44). We did not observe any evidence of ER stress in islets after 
Nnat inactivation in vivo (data not shown), with in vitro studies 
indicating a defect in preproprotein translocation on the cytoso-
lic side of the ER membrane, where the bulk of the NNAT protein 
resides. Pulse-chase and immunofluorescence analysis further 
suggested that untranslocated preproinsulin is degraded in the 
cytosol. Consistent with this lack of ER stress, the proinsulin/
mature insulin ratio in mutant islets was unaltered, indicating that 
processing of the C-peptide, downstream of the SP processing 
event cleavage and mediated by prohormone convertases (PCSK1 
and PCSK2) and carboxypeptidase E (CPE), was unaffected. It is 
therefore clear that loss of neuronatin does not cause an absolute 
block in preproinsulin SP cleavage, as can occur in severe forms 
of MIDY. This may explain the lack of development of progressive 
diabetes in Nnat-deficient mice despite the presence of a severe 
defect in GSIS and glucose intolerance under nutrient overload, 
due to the absence of ER stress and subsequent β cell failure that 
can result from the accumulation of misfolded insulin species.
Instead, β cell Nnat deficiency in mice causes loss of appro-
priate insulin secretion control, with complete absence of glu-
cose-evoked insulin release and glucose intolerance under con-
ditions of nutrient excess. The mildly increased basal insulin 
secretion observed in vivo, but not in primary islets, likely stems 
from compensatory responses to lack of GSIS during periods of 
increased demand, i.e., feeding. This is perhaps the reason, togeth-
er with the lack of a destructive islet phenotype and preservation 
of β cell mass, for the absence of glucose intolerance in chow-fed 
β cell–specific Nnat-deficient mice. However, this compensatory 
basal hyperinsulinemia was lost when these mutant mice were 
chronically challenged with a Western diet. Moreover, unlike 
control animals, the mutant mice failed to adequately increase 
basal insulin levels upon overnutrition, resulting in hyperglyce-
neuronatin function thus results in a defect in GSIS both in vitro 
and in the living animal.
The majority of secreted proteins are synthesized with an 
amino-terminal SP, directing them into the secretory pathway via 
the ER. Here, the membrane-bound SPC cleaves the SP, an essen-
tial step in the maturation and eventual secretion of the mature 
protein (32, 33). In mammals, the SPC consists of 5 subunits: 
SEC11A and SEC11C, which are responsible for the catalytic activ-
ity and are present in the ER lumen (31, 34, 35); and SPCS1, SPCS2, 
and SPCS3. SPCS1 and SPCS2, which are found on the cytosolic 
face, appear to affect proteolytic efficiency without possessing 
intrinsic catalytic activity, possibly by mediating preproprotein 
translocation across the ER membrane (30, 36–39). We show that 
in pancreatic β cells NNAT is located on the cytosolic face of the 
ER, presumably interacting with SPCS1 and SPCS2, where it pro-
motes translocation but not targeting of nascent proinsulin into 
the ER. In contrast, we obtained little evidence for localization to 
the plasma membrane as suggested by others (21).
Our loss-of-function studies demonstrate that NNAT is 
required for efficient SP cleavage of preproinsulin by the SPC in 
β cells. Thus, disruption of this step results in reduced intracel-
lular proinsulin and would appear, therefore, to lead to a defect 
in mature insulin storage and secretion, with mice lacking Nnat 
either globally or specifically in β cells displaying impaired GSIS. 
Interestingly, we have been unable to find previous published 
evidence to suggest that this early stage of insulin processing by 
the SPC is subject to specific regulation, and, consequently, it has 
been assumed that this step is constitutive in nature. Our RNAi 
studies in the INS1E β cell line demonstrate the importance of ade-
quate SPC activity for insulin maturation and that early defects are 
able to propagate through the system and result in blunted GSIS. 
Furthermore, a key role for appropriate cleavage of the insulin 
SP in normal glucose homeostasis has previously been revealed 
by the identification of rare human genetic mutations within the 
Figure 6. Regulation of NNAT expression in islets by glucose and diet. (A) Quantitative RT-PCR analysis 
of Nnat mRNA in isolated islets from 10-week-old male WT C57BL/6J mice cultured in low-glucose (3 
mM) or high-glucose (16.7 mM) conditions for 6 hours. Hprt mRNA was used as an internal control, and 
data are compared with 3-mM cultures (n = 5 animals per group, Mann-Whitney U test). (B) Parallel islet 
preparations receiving the same treatment as in A were analyzed for protein expression by Western 
blotting. β-Tubulin was used as a loading control. (C) Representative Western blot analysis of NNAT pro-
tein expression in isolated pancreatic islets of 10-week-old male WT C57BL/6J mice that were chow-fed 
(Fed), fasted overnight (Fasted), or fed high-fat diet for 72 hours (HFD). Similar experiments were also 
performed with 72-hour feeding with Western diet (Western) compared with chow-fed controls (Chow). 
β-Tubulin was used as a loading control (n = 5 animals per group, Kruskal-Wallis for HFD studies, left pan-
els, and Mann-Whitney U test for Western diet studies, right panels). Mean values for each condition are 
shown below each panel, compared with chow-fed controls. (*P < 0.05, **P < 0.01.)
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Methods
Reagents. Mouse monoclonal antibodies against insulin (clone 
K36AC10, I2018, for immunostaining of paraffin sections), FLAG 
(M2, F1804), β-tubulin (DM1A, T9026), and glucagon (K79bB10, 
G2654) were from Sigma-Aldrich. Rabbit polyclonal antibodies 
against glucagon (ab92517), NNAT (ab27266), VAPB (ab72470), and 
ribophorin 1 (ab198508) and mouse monoclonal antibodies against 
PDI (RL90, ab2792) were from Abcam. Mouse anti-insulin (L6B10, 
8138, for immunoblotting/immunofluorescence), anti–c-Myc (9B11, 
2276), and anti-IRE1α (14C10, 3294) were purchased from Cell Sig-
naling. MG132 was purchased from Sigma-Aldrich.
Animal models. Experiments involving animals were designed 
and reported following Animal Research: Reporting of In Vivo Exper-
iments (ARRIVE) guidelines. Power calculations for numbers of mice 
for each experiment were based on reported or known effect sizes and 
variation, in order to maximize chances of meaningful results without 
the unnecessary use of experimental animals. Where possible, inves-
tigators were blinded to the genotype of both study animals and tis-
sue/blood samples. For experiments involving treatments, mice were 
randomized by genotype for study groups, or a crossover design was 
used where indicated. All metabolic studies were replicated in at least 
2 independent cohorts.
A floxed Nnat allele was created by homologous recombination in 
embryonic stem (ES) cells. LoxP sites were introduced flanking exon 1 
of the Nnat gene, with a neomycin cassette flanked by FRT sites used as 
a selectable marker (GenOway). 129S2/SvPas ES cells were transfected 
with linearized targeting vector JSC1-HR by electroporation, and DNA 
from clones screened by Southern blotting and PCR. ES cells were inject-
ed into blastocysts, which were implanted into pseudopregnant females 
and chimeric male mice screened for germline transmission. Flp-mediat-
ed excision to delete the neomycin selection cassette (Neo) was performed 
in vivo by breeding of mutant animals with ubiquitous Flp recombinase–
expressing deleter mice, to produce a floxed Nnat allele (Nnat+/fl). Mice 
with constitutive deletion of Nnat were then created by intercrossing of 
the Nnat+/fl line with a Cre recombinase–expressing germline deleter 
strain in order to generate a null version of this allele (Nnat+/–). Both of 
these mouse lines were backcrossed in our transgenic animal facility more 
than 8 times onto C57BL/6J or 129S2/Sv backgrounds before intercross-
ing of mutant animals for generation of experimental cohorts. The pres-
ence of the mutant allele was determined by PCR analysis of DNA from 
ear tissue biopsies. A common upstream primer (5′-TGGTCTACTTCTC-
CATAAAGCTCGCTCC-3′) and primers specific for the WT allele 
(5′-GATCTTTTCTGACTGTTGGTTCCCGC-3′) and a region down-
stream of the excised sequence (5′-AAGGGGCATTTTTTTCTCTAGT-
GTGTTTCC-3′) were used for amplification. To delete Nnat specifical-
ly in pancreatic β cells, Nnat+/fl mice were crossed with transgenic mice 
expressing Cre recombinase at the Ins1 locus (23) to generate mice with 
conditional deletion of Nnat in β cells.
Experimental cohorts of group-housed, male mutant mice and 
their control littermates were maintained on a 12-hour light/12-hour 
dark cycle with free access to water and standard mouse chow (RM3, 
Special Diet Services) and housed in specific pathogen–free barrier 
facilities. All animal work was carried out in accordance with the UK 
Animals (Scientific Procedures) Act (1986). High-fat diet (D12451; 
45% energy from fat, 35% energy from carbohydrate) and high-sugar/
high-fat Western diet (D12079B; 40% energy from fat, 43% energy 
from carbohydrate) were both purchased from Research Diets.
mia and progressive glucose intolerance when exposed to this 
challenge. This abnormality was not due to a reduction in β cell 
mass on this diet, further suggesting a functional deficit in insu-
lin production and release. The development of hyperglycemia 
may, in turn, propagate the defect in islet function through gluco-
toxicity, although our data do not suggest that this is an initiating 
event underlying the defective GSIS. We also observe that NNAT 
expression in β cells is rapidly responsive to acute changes in nutri-
ent conditions both in vitro and in vivo and therefore appears to 
regulate β cell function in response to overnutrition.
Our studies also provide important insights into the previ-
ously proposed mechanisms through which neuronatin regulates 
cell physiology. Overexpression studies in vitro in both β cell and 
adipocyte cell lines had suggested that neuronatin regulates intra-
cellular calcium handling (5, 14). In contrast, the present detailed 
studies of Ca2+ dynamics in Nnat-null primary β cells failed to 
reveal any defects. These findings strongly suggest that neurona-
tin is unlikely to be involved in shaping Ca2+ signals in these cells 
and specifically in the proximal calcium-dependent events under-
pinning glucose sensing (45). Furthermore, it does not appear that 
NNAT is present on insulin secretory granules itself. The role of 
NNAT in regulating SP cleavage and the ER localization of NNAT 
and its binding partners therefore point to a major role during ini-
tial peptide handling rather than other events involved in GSIS. 
While our studies cannot categorically exclude roles for neuro-
natin in other components of the complex processes by which β 
cells synthesize and secrete insulin in response to glucose (indeed 
we find that neuronatin associates with components of the COPII 
machinery), we believe that defects in SP processing and subse-
quent granule loading are likely to account for the major part of 
the observed defect in β cell function. Indeed, it should also be 
noted that in our studies involving knockdown of Sec11a, which 
is thought to specifically function as a component of the SPC, we 
observe a reduction in insulin storage and secretion. This finding 
suggests that defective SPC function alone can lead to the pheno-
types we observe upon Nnat deficiency in vitro and in vivo.
Previous studies have also indicated that neuronatin may play 
a role in the central nervous system regulation of metabolism, and 
in particular body weight, as its expression in specific hypotha-
lamic regions is regulated by leptin and nutrients (12, 13). Further-
more, rare single-nucleotide polymorphisms at the human NNAT 
locus are associated with extreme childhood obesity (17). The lack 
of marked body weight, feeding, or energy expenditure pheno-
types in Nnat-null mice, plus preserved sensitivity to exogenous 
leptin, suggests that neuronatin does not play a major role in these 
aspects of energy metabolism.
In summary, we demonstrate an unexpected role for neurona-
tin in the control of early preproinsulin SP cleavage, which leads 
to marked deficits in insulin storage and secretion, thus defining a 
previously unrecognized site of nutrient-sensitive control of β cell 
function and whole-animal glucose homeostasis. Importantly, the 
requirement for neuronatin in SP cleavage, and the expression of 
this protein in a range of neuronal, adipose, and endocrine cell 
types involved in the regulation of metabolism and growth, sug-
gest additional roles in neuroendocrine cell secretion and the reg-
ulation of energy homeostasis. Future studies will be required to 
explore these possibilities.
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the Reagents section) and secondary antibodies (Alexa Fluor 488 and 
594, Invitrogen). Cells were mounted on glass slides and imaged using 
a TCS SP5 II Confocal microscope (Leica).
Immunoprecipitation and mass spectrometry. MIN6 cells (24) grown 
in standard culture conditions (DMEM, 10% FBS, 2 mM l-glutamine, 
50 μM β-mercaptoethanol, 37°C, 5% CO2) were homogenized in pro-
tein lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton 
X-100, 1 mM EDTA with protease inhibitors [Complete Mini, Roche]), 
clarified, and normalized for protein content. Supernatants were incu-
bated with protein A-agarose beads (Calbiochem) and antibodies 
against NNAT (rabbit polyclonal, Abcam) or rabbit IgG (control immu-
noprecipitate) rotating at 4°C overnight. Beads were washed 4 times 
with lysis buffer, boiled in Laemmli buffer, and run on SDS-PAGE, 
and gels were stained with Coomassie (SimplyBlue, Invitrogen). Each 
lane was excised into bands and placed into separate protein LoBind 
(Eppendorf) Eppendorf tubes for proteomic analysis by mass spec-
trometry. Coomassie was removed from bands by incubation with 
50 mM ammonium bicarbonate, 10% acetonitrile for 30 minutes at 
room temperature and gel pieces dehydrated for 10 minutes. Disulfide 
bonds were reduced using 10 mM DTT and free thiol groups alkylat-
ed with 55 mM iodoacetamide. Modified porcine trypsin (Proteomics 
Grade, Sigma-Aldrich) was added to each gel piece to a final amount 
of 0.5 μg and incubated overnight at 37°C, with tryptic digestion halt-
ed by addition of 5% formic acid. Peptide-containing solutions were 
dried in a vacuum centrifuge, before peptides were solubilized in 30 
μl of 0.1% trifluoroacetic acid (TFA) and placed in autosampler vials 
ready for liquid chromatography/mass spectrometry injection.
Peptides were separated using an UltiMate 3000 nano liquid 
chromatography system (Thermo Fisher Scientific) before mass spec-
trometric analysis. Five microliters of sample was loaded onto a trap 
column (Acclaim Pepmap 100; 100 μm × 2 cm, C18) at 8 μl/min in 2% 
acetonitrile, 0.1% TFA. Peptides were then eluted online to an analyti-
cal column (Acclaim Pepmap RSLC; 75 μm × 25 cm, C18) and separat-
ed using a ramped gradient. Eluted peptides were analyzed by an LTQ 
Velos Orbitrap mass spectrometer operating in positive polarity data- 
dependent acquisition mode. Ions for dissociation were determined 
from an initial 15,000-resolution mass spectrometric survey scan (event 
1) followed by collision-induced dissociation (CID) of the top 10 most 
abundant ions (500 count threshold). CID conditions were default 
charge state 2, 2.0 m/z isolation width, normalized collision energy 
35.0, activation Q value 0.25, activation time 10 milliseconds, lock mass 
value 445.120030 m/z. Progenesis QI for Proteomics (Waters Corp.) 
software was used to align all raw data files, perform peak picking, and 
produce features for export as.mgf files. Mascot and Mascot Daemon 
v2.5.1 (Matrix Science) were used to search.mgf files against the Swiss-
Prot Mus musculus database (https://www.uniprot.org/) (downloaded 
November 26, 2014, containing 16,686 sequences). A reversed decoy 
was implemented by Mascot, and results were filtered to 1% false discov-
ery rate. Search parameters included: 10 ppm MS1 tolerance, 600 milli 
mass unit MS2 tolerance, maximum of 2 missed cleavages, fixed modi-
fication of cysteine carbamidomethylation, and variable modifications 
of methionine oxidation and protein N-terminal acetylation. Resulting 
Extensible Markup Language (XML) files were returned to Progenesis 
and proteins filtered for those containing at least 1 unique peptide and 
identified in all 3 biological replicates. Intensity normalization was per-
formed by Progenesis, and proteins were ranked by fold change increase 
in abundance compared with control immunoprecipitates.
Metabolic analysis. Measurement of body weights, tail vein blood 
collection, and determination of blood glucose levels using a Con-
tour glucometer (Bayer) were all performed as previously described 
(46). Intraperitoneal glucose (2 g/kg) and insulin (0.75 IU/kg) toler-
ance tests as well as intraperitoneal GSIS (3 g/kg) were performed as 
previously described (47) with blood collection at times indicated in 
the figures. Assessment of food intake and leptin sensitivity was per-
formed in singly housed mice for 3 consecutive experimental days as 
previously described (46) using 1.5 mg/kg recombinant mouse leptin 
(R&D Systems). Levels of mature insulin (no cross-reactivity with pro-
insulins) were determined by ELISA (Crystal Chem), and levels of pro-
insulin and glucagon were determined by ELISA (Mercodia).
Primary islet isolation and GSIS. For islet isolation, the pancreas 
was injected with Liberase TM (Roche), digested at 37°C, and islets 
purified using a Histopaque gradient (Sigma-Aldrich), and handpicked 
as previously described (48). For secretion studies, isolated islets were 
cultured overnight in RPMI supplemented with 10% FBS. Following a 
30-minute preincubation in Krebs-HEPES-bicarbonate buffer (KHB; 
140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.2 mM MgSO4, 1.5 mM 
CaCl2, 10 mM HEPES, 25 mM NaHCO3) with 3 mM glucose, GSIS was 
assessed by static incubation of 6 size-matched islets in KHB with 3 
mM or 16.7 mM glucose for 30 minutes at 37°C. Mature insulin secret-
ed into the media and total mature insulin content of the islets were 
assayed by ELISA (Crystal Chem; no cross-reactivity with proinsulins).
Calcium imaging. Intracellular free Ca2+ was imaged in KHB sat-
urated with 95% O2/5% CO2 and adjusted to pH 7.4, with additions 
as stated in the figures. Islets were incubated at 37°C for 45 minutes 
in KHB containing 10 μM Fluo-2-AM (Cambridge Biosciences). Islets 
were then transferred in a perfusion chamber, mounted on a Zeiss Axio-
vert confocal microscope, and continuously perfused at 34°C–36°C. 
Fluo-2 was excited with a 491-nm laser line and emitted light filtered 
at 525/50 nm. Images were acquired with a Hamamatsu ImagEM cam-
era, and Volocity software (PerkinElmer) was used for data capture. 
Traces are presented as normalized intensity over time (F/F0) (49).
Transmission electron microscopy. Isolated islets were fixed in 4% 
paraformaldehyde (PFA)/0.2% glutaraldehyde in PBS at 4°C overnight 
immediately upon extraction. Samples were washed 3 times with cac-
odylate buffer (Electron Microscopy Sciences [EMS]) and osmicated 
with osmium tetroxide in 2% (wt/vol) cacodylate buffer for 1 hour. 
Samples were then washed 5 times with deionized water and dehy-
drated through a graded ethanol series. After dehydration, samples 
were infiltrated with Epon Resin (EMS) diluted in ethanol at 3:1, 2:1, 
and 1:1 for 1 hour each, and then overnight at 1:2. The solution was then 
replaced with pure resin, which was changed twice in the first 12 hours 
and then allowed to infiltrate again overnight. Samples were imme-
diately placed in an oven at 60°C and left to cure overnight. Curetted 
resin blocks were sectioned at 100 nm using an ultramicrotome (Leica) 
and immediately placed on copper grids. These grids were imaged in a 
transmission electron microscope at 80 kV (JEOL 2000FX TEM).
Histological techniques and immunofluorescence. Dissected pan-
creata were fixed in Bouin’s solution, embedded in paraffin, and cut 
into 5-μm sections. Insulin (mouse monoclonal, Sigma-Aldrich) and 
glucagon (rabbit polyclonal, Abcam) immunostaining and morpho-
metric analysis were performed blindly as previously described using 
a DMRB Fluorescence microscope (Leica) (46). Dispersed islets and 
INS1E cells grown overnight on poly-l-lysine coverslips were fixed in 
4% PFA, permeabilized, and immunostained with primary (listed in 
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Cellular membrane preparation. INS1E cells were homogenized in 
a hypotonic buffer (50 mM Tris-HCl, pH 7.5, 50 mM mannitol, 1 mM 
EDTA with protease inhibitors) and cleared by centrifugation at 1,000 
g for 10 minutes at 4°C. The supernatant was layered on a mannitol 
cushion (same buffer as above but 300 mM mannitol) and ultracen-
trifuged (Optima TLX Ultracentrifuge, Beckman Coulter) at 60,000 g 
for 60 minutes at 4°C. Both the crude membrane pellet and the super-
natant were resuspended in Laemmli buffer and boiled and proteins 
analyzed by Western blotting using antibodies against NNAT (rabbit 
polyclonal, Abcam), VAPB (rabbit polyclonal, Abcam), and β-tubulin 
(mouse monoclonal, Sigma-Aldrich).
Expression analysis. Snap-frozen tissues or cells were homogenized 
directly into Trizol reagent for RNA analysis or lysis buffer (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA with 
protease inhibitors [Complete Mini, Roche]) for protein work. mRNA 
was extracted using RNeasy kits (Qiagen) and normalized for cDNA 
synthesis, and expression was assessed by quantitative RT-PCR using 
TaqMan reagents on a 7900HT Real Time PCR cycler (all Applied 
Biosystems). A complete list of probes used for quantitative RT-PCR is 
available in Supplemental Table 2. Protein expression was analyzed by 
Western blotting from clarified lysates normalized for protein content 
by BCA method (Bio-Rad), all as previously described (46). A com-
plete list of primary antibodies can be found in the Reagents section.
Signal peptidase assay. Cell-free cleavage of SP from preprohor-
mones in vitro has been described previously (28, 29). Briefly, cDNAs 
for Preproinsulin2 and subunit components of the SPC (Sec11a and 
Spcs3), all with a C-terminal c-Myc tag (purchased from Origene), 
as well as C-terminal FLAG-tagged full-length Nnat and untagged 
Gfp were PCR-amplified and ligated into the MscI/SalI sites of the 
pT7CFE1.CHis vector. Stop codons were included after each tag to 
prevent expression of the endogenous His tag. Proteins were translat-
ed from these constructs in vitro using a human (HeLa-based) in vitro 
translation kit (Pierce) by incubation at 30°C for 90 minutes. Where 
indicated, canine pancreatic microsomes (Promega) were included in 
the reaction. A standard concentration of pancreatic microsomes was 
used per reaction as a source of SPC, which generated partial (~50%) 
processing of the total amount of preproinsulin, but allowed a signif-
icant proportion of unprocessed preproinsulin in order to determine 
augmenting effects of exogenous NNAT on these processing dynam-
ics. Samples from 3 independent experiments were boiled in Laemmli 
buffer and the abundance of proteins in these reactions determined 
using Western blotting with anti–c-Myc and -FLAG antibodies.
NNAT membrane topology. For orientation of NNAT on the micro-
somal membrane, 90-minute translations expressing NNAT, SPCS3, 
or SEC11A were adjusted to a final concentration of 2 mM CaCl2, and/
or 10 μg/ml proteinase K, and/or 1% Triton X-100 where indicated, 
and transferred to ice for 30 minutes. Addition of Triton X-100 deter-
gent to disrupt microsomes served as a positive control for proteinase 
K activity. Proteolysis was terminated by addition of PMSF, and sam-
ples from 3 independent experiments were boiled in Laemmli buffer 
before analysis by Western blotting using antibodies against c-Myc 
and FLAG, essentially as previously described (31).
Statistics. Assessment of normal distribution (D’Agostino-Pearson 
normality test) and also statistical significance between groups was 
determined using GraphPad Prism 7 by 2-tailed Student’s t test or 
ANOVA, or Mann-Whitney U or Kruskal-Wallis tests as the nonpara-
metric equivalent. Bonferroni (or Dunn’s for nonparametric) and 
For validation experiments in HEK293T cells (cultured in DMEM, 
10% FBS, 2 mM l-glutamine, 37°C, 5% CO2), cells were transfected 
with plasmids expressing C-terminal c-Myc–tagged SEC11A (Origene) 
and C-terminal FLAG-tagged mouse NNAT in pcDNA3.1 (BamHI/
XhoI sites) using Lipofectamine 2000. Forty-eight hours later, trans-
fected cells were lysed, clarified, normalized as above, and immuno-
precipitated using anti–c-Myc agarose resin (Pierce) with Western 
blotting performed using antibodies against c-Myc (mouse monoclo-
nal, Cell Signaling) and FLAG (mouse monoclonal, Sigma-Aldrich).
siRNA knockdown. For siRNA silencing, INS1E cells (50) (cultured 
in RPMI, 10% FBS, 2 mM l-glutamine, 50 μM β-mercaptoethanol, 
37°C, 5% CO2) were transfected with 50 nM of Silencer Select siRNAs 
(Nnat, s137247; Sec11a, s80747; both Ambion) using Dharmafect 1 
reagent (Dharmacon). After 24 hours, cells were incubated overnight 
in cell culture medium with 3 mM glucose. For GSIS the following day, 
cells were incubated for 30 minutes in KHB with 3 mM glucose at 37°C 
and then with 3 mM glucose or 25 mM glucose for a further 30 minutes 
at 37°C. Insulin secreted into the media and total cellular insulin con-
tent were assayed by ELISA (Crystal Chem).
Pulse-chase analysis. Radiolabeling was performed in INS1E cells with 
transient transfection of C-terminal c-Myc–tagged mouse Preproinsulin2 
(Origene) and siRNAs. Forty-eight hours after transfection, cells were 
pulse-labeled with 35S-methionine/cysteine (PerkinElmer) for 15 minutes 
and chased with unlabeled media where indicated, essentially as previ-
ously described (40, 41). Cells were homogenized in protein lysis buffer 
as above and centrifuged at 16,000 g for 10 minutes at 4°C. Cell lysates 
and chase media were immunoprecipitated using c-Myc agarose resin 
(Pierce), and analyzed by SDS-PAGE and standard autoradiography tech-
niques including enhancement with Amplify reagent (GE Healthcare).
ER targeting assay. For assessment of preproprotein targeting to 
the ER, INS1E cells were transfected with preproinsulin 2 and siRNAs 
as above with the inclusion of a vector expressing c-Myc–tagged mouse 
GAPDH (Origene) and radiolabeled for 15 minutes. Cells were then 
washed and resuspended in 50 μl of 50 mM HEPES, 150 mM NaCl, 
2 mM CaCl2, pH 7.5, with protease inhibitors with or without 0.01% 
digitonin for 10 minutes on ice. Cells were centrifuged at 16,000 g for 
10 minutes at 4°C, after which 450 μl of protein lysis buffer (1% Tri-
ton X-100, as above) was transferred to the supernatant and the pellet 
lysed in 500 μl protein lysis buffer. Both supernatant and pellet were 
immunoprecipitated with c-Myc agarose resin and analyzed by auto-
radiography as above, all as described previously (40, 41), and with 3 
independent experiments performed.
Assays in partially permeabilized cells. For membrane orientation of 
NNAT in INS1E, cells grown on poly-l-lysine coverslips were fixed with 
4% PFA, permeabilized with either 0.01% digitonin or Triton X-100, 
and immunostained with antibodies against NNAT (rabbit polyclonal, 
Abcam) or PDI (mouse monoclonal, Abcam). Images were acquired 
using a TCS SP5 II Confocal microscope (Leica), all as previously 
described (40). To assess preproinsulin translocation across the ER 
membrane, INS1E cells were grown on poly-l-lysine coverslips, with 
siRNA-mediated knockdown of Nnat for 48 hours. Cells were pretreat-
ed with 10 μΜ MG132 for 4 hours before fixation and permeabilized 
with either digitonin or Triton X-100 as above, and immunostaining 
was performed using antibodies against preproinsulin/mature insu-
lin (Cell Signaling), NNAT, and PDI. Both of these experiments were 
performed at least 3 times independently, and representative images 
shown are maximum projections from 3-step Z-stacks 0.5 μm apart.
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